ZAI LAB LTD (ZLAB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$26.23-2.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ZLAB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||
| Revenues | 449.6 | 460.2 | 399.0 | 266.7 | 215.0 | 144.3 | 49.0 | 13.0 | 0.1 | — |
| Total Revenues | 449.6 | 460.2 | 399.0 | 266.7 | 215.0 | 144.3 | 49.0 | — | — | — |
| Cost of Revenues | 195.5 | 190.5 | 147.1 | 95.8 | 74.0 | 52.2 | 16.7 | 3.7 | 0.0 | — |
| Gross Profit | — | — | — | — | — | — | — | — | 0.1 | — |
| Operating Expenses & Income | ||||||||||
| Selling, General & Admin | 281.1 | 277.6 | 298.7 | 281.6 | 259.0 | 218.8 | 111.3 | 70.2 | 21.6 | — |
| R&D Expenses | 236.9 | 220.9 | 234.5 | 265.9 | 286.4 | 573.3 | 222.7 | 142.2 | 120.3 | 39.3 |
| Operating Income | (264.1) | (229.4) | (282.1) | (366.6) | (404.4) | (700.1) | (301.8) | (203.2) | (141.8) | (51.4) |
| Earnings from Continuing Operations | ||||||||||
| Interest Expense | — | 5.2 | 2.3 | 0.0 | 0.0 | 0.0 | 0.2 | 0.3 | 0.0 | — |
| Interest & Investment Income | 27.9 | 33.0 | 37.1 | 39.8 | 14.6 | 2.2 | 5.1 | 8.2 | 3.3 | 0.5 |
| Net Interest Expenses | — | — | — | (39.8) | (14.6) | (2.2) | (4.9) | (7.9) | (3.2) | — |
| EBT, Incl. Unusual Items | (190.7) | (178.5) | (257.1) | (334.6) | (443.1) | (703.4) | (267.8) | (194.3) | (138.5) | (50.1) |
| Income Tax Expense | — | (2.9) | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | ||||||||||
| Net Income | (188.2) | (175.5) | (257.1) | (334.6) | (443.3) | (704.5) | (268.9) | (195.1) | (139.1) | (50.4) |
| Per Share | ||||||||||
| Basic EPS | (0.17) | (0.16) | (0.26) | (0.35) | (0.46) | (0.76) | (0.35) | — | — | — |
| Diluted EPS | (0.17) | (0.16) | (0.26) | (0.35) | (0.46) | (0.76) | (0.35) | — | — | — |
| Revenue per Share | 0.40 | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 1,117.0 | 1,095.3 | 989.5 | 966.4 | 958.1 | 929.9 | 776.7 | — | — | — |
| Diluted Weighted Avg Shares | 1,117.0 | 1,095.3 | 989.5 | 966.4 | 958.1 | 929.9 | 776.7 | — | — | — |
| Supplemental | ||||||||||
| EBITDA | — | (214.4) | (270.3) | (357.5) | (396.1) | (693.6) | (297.2) | (199.4) | — | — |
| EBIT | (264.1) | (229.4) | (282.1) | (366.6) | (404.4) | (700.1) | (301.8) | (203.2) | (141.8) | (51.4) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.